Steady growth of bladder cancer (BC) incidence rate and large quantity of its mutations presumes considerably high immunogenicity of tumor cells, and, correspondingly, its sensitivity to immunotherapy. Development of personalized dendritic cell antitumor vaccines (PDATV) against BC is the actual problem, which covers many aspects, necessary for its standardization. The article presents own experimental findings related to development of optimal conditions of transportation of biomaterials; temperature and time modes of storage of samples were defined; comparative analysis of different methods of tumor disaggregation was performed, based on evaluation of vitality of autologous cells of urothelial carcinoma (CUC) in the process of their cultivation for the purpose of creation of PDATV against BC. Thus, we have worked out optimal parameters for preservation of viability of autologous CUC in the process of transportation and storage of biomaterial from BC patients, requiring performance of PDATV immunotherapy from remote health facilities.